New Mexico Administrative Code › Title 16 - OCCUPATIONAL AND PROFESSIONAL LICENSING › Chapter 10 - MEDICINE AND SURGERY PRACTITIONERS › Part 14 - MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES › Section 16.10.14.7 - DEFINITIONS

Current through Register Vol. 35, No. 13, July 16, 2024
A.
"Acute
				pain"
means the normal, predicted physiological response to a noxious
				chemical or thermal or mechanical stimulus, typically associated with invasive
				procedures, trauma or disease and is generally time-limited.
B.
"Addiction"
is a
				neurobehavioral syndrome with genetic and environmental influences that results
				in psychological dependence on the use of substances for their psychic effects.
				It is characterized by behaviors that include one or more of the following:
				impaired control over drug use; compulsive use; continued use despite harm;
				and, craving. Physical dependence and tolerance are normal physiological
				consequences of extended opioid therapy for pain and should not by themselves
				be considered addiction.
C.
"Benzodiazepine"
means any controlled substance referenced at
				Subsection A of
				16.19.20.68 NMAC, as
				may be amended from time to time.
D.
"Chronic pain"
means pain
				that persists after reasonable medical efforts have been made to relieve the
				pain or its cause and that continues, either continuously or episodically, for
				longer than three consecutive months. "Chronic pain" does not, for purpose of
				the Pain Relief Act requirements, include pain associated with a terminal
				condition or with a progressive disease that, in the normal course of
				progression, may reasonably be expected to result in a terminal
				condition.
E.
"Clinical
				expert"
means a person who, by reason of specialized education or
				substantial relevant experience in pain management, has knowledge regarding
				current standards, practices and guidelines.
F.
"Controlled Substance"
means
				a drug or substance listed in schedules I through V of the Controlled
				Substances Act or regulations adopted thereto.
G.
"Delegate"
means a person
				designated by a practitioner pursuant to
				16.19.29.9
				NMAC for the purpose of requesting and receiving prescription monitoring
				program (PMP) reports for that practitioner.
H.
"Opioid"
means the class of
				drugs that includes the natural derivatives of opium, which are morphine and
				codeine, and related synthetic and semi-synthetic compounds that act upon
				opioid receptors.
I.
"Opioid
				antagonist"
means a drug approved by the federal food and drug
				administration that when administered negates or neutralizes in whole or in
				part the pharmacological effects of an opioid analgesic in the body, including
				naloxone and such other medications approved by the board of pharmacy for the
				reversal of opioid analgesic overdoses.
J.
"Pain"
means acute or chronic
				pain or both.
K.
"Physical
				dependence"
means a state of adaptation that is manifested by a
				drug-specific withdrawal syndrome that can be produced by abrupt cessation,
				rapid dose reduction, decreasing blood level of the drug, administration of an
				antagonist, or a combination of these.
L.
"Practitioner"
means a New
				Mexico medical board licensee maintaining licensure pursuant to state law that
				allows that individual to prescribe, order, administer or dispense controlled
				substances to patients (see
				16.19.29.7
				NMAC).
M.
"Prescription
				monitoring program"
means a centralized system to collect, monitor, and
				analyze electronically, for controlled substances, prescribing and dispensing
				data submitted by pharmacies and dispensing practitioners. The data are used to
				support efforts in education, research, enforcement and abuse
				prevention.
N.
"Schedule
				II-V"
refers to any controlled substance listed in schedule II, III, IV,
				or V of the Controlled Substances Act found at Chapter 30, Article 31 NMSA
				1978, regulations promulgated by the New Mexico board of pharmacy found at
				16.19.20 NMAC, or federal controlled substances regulations promulgated
				pursuant to
				21 U.S.C.
				812.
O.
"Stimulant"
means any
				controlled substance referenced in Subsection C of
				16.19.20.66 NMAC,
				Subsection A of
				16.19.20.67 NMAC,
				Subsection D of
				16.19.20.68 NMAC, or
				Subsection B of
				16.19.20.69
				NMAC, as may be amended from time to time.
P.
"Therapeutic purpose"
means
				the use of pharmaceutical and non-pharmaceutical medical treatment that
				conforms substantially to accepted guidelines for pain management and other
				conditions.
Q
"Tolerance"
means a state of adaptation in which exposure to a
				drug induces changes that result in a diminution of one or more of the drug's
				effects over time.